Vietnam healthcare market: size, growth and outlook 2026–2032

Fast-growing, import-dependent and consolidating into private groups. Published estimates normalised to 2025 range from USD 10.7 bn to USD 26.8 bn; the Consulting Wallah central estimate is USD 16.0 bn, growing at about 8% a year to USD 26.7 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by near-universal social health insurance (94.2% coverage; VND 142.9 tn disbursed 2024); rising NCD burden (84% of deaths in 2024 vs ~74% in 2022) and ageing (8.1% aged 65+); growing middle class; private spending growing ~7.5% CAGR; outpatient private share already 32%.

Context that matters for buyers and suppliers: Vietnam has ~1,531 hospitals, over 86% public; private sector holds only 6% of beds but 49.5% of health spending. Bed density 317 per 100,000 (2022): 295 public, 22 private. Social health insurance covered 94.2% of population by late 2024 with 186.2 mn visits and VND 142.9 tn disbursed. 80-90% of medical device sales are imports; Vietnam is 4th-largest device importer in SE Asia.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 10.7 bn–USD 26.8 bn; differences are mostly scope.

Included: public and private hospital, clinic, diagnostic and long-term care services and the associated health expenditure. Excluded: pharmaceutical and device product sales, insurance premiums and health IT (covered in separate reports). Published totals differ mainly by whether products and insurance are folded in.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Vietnam has ~1,531 hospitals, over 86% public; private sector holds only 6% of beds but 49.5% of health spending (The Investor)
• Bed density 317 per 100,000 (2022): 295 public, 22 private (GTAI)
• Social health insurance covered 94.2% of population by late 2024 with 186.2 mn visits and VND 142.9 tn disbursed (Nexdigm)
• 80-90% of medical device sales are imports; Vietnam is 4th-largest device importer in SE Asia (GTAI)
• Largest device import lines 2022: orthopaedics USD 371 mn, therapy/respiratory USD 199 mn, other instruments USD 194 mn (GTAI (UN Comtrade))
• Health spending ~4.6-5% of GDP, USD 185 per capita; OOP ~45% (GTAI)
• FV Hospital (220 beds, opened 2003) acquired by Thomson Medical for USD 381.4 mn (Jan 2024) (The Shiv)
• Public hospital occupancy often exceeds 120-130% (Nexdigm)
• Private providers deliver 6.3% of inpatient and 32.2% of outpatient care in major cities (The Investor (Viettonkin))

Where the GCC and India sit

• Hospitals: ~1,531 hospitals, >86% public (2023) — The Investor
• Bed density: 31.7 beds per 10,000 (29.5 public, 2.2 private) in 2022; targets 33 (2025), 35 (2030), 45 (2050) per 10,000 (2022) — GTAI; LuatVietnam (Decision 201/QD-TTg)
• Social health insurance coverage: 94.2% of population (end-2024), 93.3% (2023); 186.2 mn visits; fund disbursement VND 142.9 tn (~USD 5.63 bn) in 2024 (2024) — Nexdigm
• Health expenditure: ~4.6-5% of GDP; USD 185 per capita (2022) (2022) — GTAI
• Doctors: 10 per 10,000 (2022); target 19 per 10,000 by 2030 (2022) — GTAI; LuatVietnam
• Population: 100.3 mn (2023), 8.1% aged 65+, life expectancy 74.5 (2023) — GTAI

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: private bed share growth from 6% to 15% by 2030 implies large private capacity build-out; medtech market growing ~9-10% p.a. to 2028; fastest in diabetes devices, cardiology, dental; pipeline of large hospitals: Trong Tung 1,200 beds (USD 140 mn), Buon Ma Thuot 1,000 beds (USD 120 mn), Can Tho cancer hospital 500 beds.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Operators and investors: capacity, payer rules and licensing timelines decide returns; design central procurement and insurer contracting into the operating model before opening.
• Suppliers: registration, a local partner and payer-formulary presence are the gates; central tenders reward structured quotations and reliable supply over the lowest price.
• Hospital leaders: payer pressure makes the 25–35% of cost in supplies the margin lever — see the free executive assessment.

1. The Investor (Flanders Investment & Trade), Vietnam health expenditure to reach $33.8 bln in 2030: analysts — theinvestor.vn
2. Nexdigm, Vietnam Healthcare Market Report — nexdigm.com
3. The Shiv, Vietnam's Healthcare Industry 2026: Growth, Investment, and Opportunities — the-shiv.com
4. GTAI, Vietnamesischer Medizintechnikmarkt kommt wieder kraeftig in Gang — gtai.de
5. LuatVietnam, Vietnam's Hospital Network Planning Strategy 2025-2030 — english.luatvietnam.vn
6. Flanders Investment & Trade (via The Investor) (2024-02) — USD 20 bn (2025E: USD 23.3 bn) (2021) to USD 33.8 bn (2030), CAGR 7.6% (private spending 7.5%); scope: country - Vietnam total health expenditure — source
7. Nexdigm (2025-07) — USD 9.91 bn hospital-sector revenue (pharma USD 7.6 bn; medical equipment USD 1.7 bn); health expenditure ~USD 17 bn (2022-23) (2024) to — (2030), CAGR —; scope: country - Vietnam hospital sector revenue; forecast behind paywall — source
8. The Shiv (citing Statista) (2026-02) — USD 9.91 bn hospitals revenue; pharma USD 2.40 bn; dental USD 4.21 bn (2023) (2024) to USD 14.25 bn hospitals; pharma USD 2.96 bn (2029), CAGR 7.53% hospitals; 4.25% pharma; 4.75% dental; scope: country - hospitals segment (Statista outlook) and sub-segments — source
9. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
10. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.